NEONATES with hypoplastic left heart syndrome and other single ventricle (SV) cardiac malformations depend on a patent ductus arteriosus for survival. The proportion of blood flow into the pulmonary (Q̇p) and systemic (Q̇s) circulation depends on the resistance of each of these circuits. Systemic arterial oxygen saturation (Sao2
) is often used to gauge relative blood flows between these circuits. Sao2
greater than 85% suggests excessive pulmonary blood flow at the expense of systemic blood flow, often resulting in insufficient vital organ perfusion and metabolic acidosis. 1
Two strategies are used to counter excessive pulmonary blood flow, namely, inspiration of hypoxic or hypercapnic gas mixtures. 2
Both strategies increase pulmonary vascular resistance and redirect blood flow to the systemic circulation.
Neonates born with SV disease sometimes experience neurologic complications in the form of seizures, impaired cognition, developmental delay, and cerebral palsy. 3,4
Although these neurologic complications are clearly multifactorial in origin, a growing body of evidence indicates that many neonates with SV experience cerebral hypoxia–ischemia before surgery. 5,6
Thus, the use of hypoxic gas mixtures raises the concern of contributing to this preoperative hypoxic–ischemic injury.
Near-infrared spectroscopy is a noninvasive optical technique used to monitor brain tissue oxygenation by measuring concentrations of oxyhemoglobin and deoxyhemoglobin, cerebral oxygen saturation (Sco2
), or cytochrome aa3
redox state. 7
This technology has been used to examine cerebral oxygenation before and during congenital heart surgery 8,9
and may also be used to examine cerebral oxygenation in response to medical therapies before and after surgery.
In this prospective, randomized, crossover trial, we examined the effect of 17% fraction of inspired oxygen (Fio2) and 3% fraction of inspired carbon dioxide (Fico2) on cerebral oxygenation and systemic hemodynamics in neonates with SV before the Norwood operation. We hypothesized that, although both treatments would improve systemic hemodynamics, 3% Fico2 would increase Sco2, whereas 17% Fio2 would decrease Sco2.
Materials and Methods
After obtaining institutional review board approval (Children's Hospital of Philadelphia, Philadelphia, PA), informed parental consent was obtained. This study was conducted between June and October 1999 at the Children's Hospital of Philadelphia. Eligibility criteria included a diagnosis of univentricular heart defect with Sao2 greater than 80% (evidence of Q̇p/Q̇s > 1.0). Exclusion criteria were postnatal age greater than 1 month, preoperative seizures, associated craniofacial anomalies that precluded near-infrared spectroscopy monitoring, and participation in an investigational drug study. The study was conducted in the operating room after induction of anesthesia and before start of stage 1 Norwood surgery.
Per institutional practice, prostaglandin infusion was discontinued immediately before transport to the operating room. No premedication was administered. After placement of electrocardiogram, pulse oximeter, and arterial pressure monitors, the subjects received fentanyl citrate (20 μg/kg bolus, then 1 μg · kg−1 · h−1) and pancuronium bromide (0.2 mg/kg), were nasally intubated, and mechanically ventilated to normocapnia with 21% Fio2 using a Servo SV 300 ventilator (Siemens-Elema, Solna, Sweden) without positive end-expiratory pressure. Heart rate, systolic arterial pressure, diastolic arterial pressure, and mean arterial pressure (MAP), Sao2 and nasopharyngeal temperature were continuously monitored during the study.
To deliver 17% Fio2 and 3% Fico2, nitrogen and carbon dioxide, respectively, were added to the inspiratory limb of the ventilator circuit. Nitrogen (size H tank) flow was adjusted to obtain 17% Fio2 as measured in the inspired limb (MaxO2 oxygen analyzer; Ceramatec, Salt Lake City, UT). Carbon dioxide (size E tank) was adjusted to achieve a partial pressure of 20 mmHg in the inspired limb (equivalent to 2.8% CO2, with a water vapor pressure of 47 mmHg at 37°C; measured using Nellcor Ultracap; Nellcor Inc., Pleasanton, CA). No changes were made to the minute ventilation during the study period.
Near-infrared Spectroscopy Methodology
The near-infrared cerebral oximeter used in this study (NIM Incorporated, Philadelphia, PA) was a prototype 3 wavelength frequency-domain device. 10
This device uses laser diodes at measuring wavelengths of 754, 785, and 816 nm with an internal reference wavelength at 780 nm. The emitted light is sinusoidally oscillated at 200 MHz, and the phase-shift and intensity of the detected light relative to the emitted light were monitored by heterodyne frequency domain technology. Fiberoptic bundles mounted in soft rubber housing (optical probe) delivered the light to and from the head, and emitter and detector were separated by 3 or 4 cm. The probe, placed on the forehead below the hairline, monitors Sco2
located in the frontal cerebrum; the scalp and skull do not contribute to the optical signal. 7,10
The main unit housing the electronic hardware sends data to a computer for storage and analysis. Sco2
is calculated from the phase shift signals. 10
Instrument precision relative to cooximetry is 6% from 0 to 100%. Near-infrared spectroscopy Sco2
represents predominantly oxygen saturation in the venous blood. 11
The protocol consisted of two treatment periods with three baseline periods (before and after each treatment). Treatments were 17% Fio2 and 3% Fico2. Arterial blood gases, arterial pressure, saturation, and cerebral saturation were obtained at the end of each period. Arterial blood gases were drawn from an indwelling umbilical arterial catheter in all subjects. The sequence of treatment was assigned randomly from a previously generated chart. Each treatment was maintained for 10 min, followed by a 10–20-min baseline period.
Sample size calculation (n = 16) was based on a power of 0.8 and α = 0.01 to detect a 20% change in Sco2 from baseline with treatment (3% Fico2 or 17% Fio2). Data are presented as mean ± SD. Significance was set at 0.01 after Bonferroni correction for multiple comparisons.
The primary outcome measure was Sco2. Secondary outcome measures included heart rate, MAP, Sao2, p H, arterial carbon dioxide tension, arterial oxygen tension, and base excess. To examine the effect of period (time effect) and the order of treatment (carryover effects), independent two-sample t tests were conducted (SPSS Inc., Chicago, IL). In the absence of time and carryover effects, and differences between baseline and the two treatments were then examined by paired t tests for parametric data (data were normally distributed). Sco2 values during the last 1-min of each period (baseline, 3% Fico2, 17% Fio2) were averaged by the computer to obtain the representative Sco2 value for that period. Change in Sco2 was the difference between treatment and the average of the baselines before and after the treatment.
Of the 16 patients enrolled, data from 15 were included in the analysis. One neonate was excluded for protocol violation (error in administering 3% Fico2
). Table 1
shows the demographic data of 15 subjects. Before the study, in the intensive care unit, all neonates had received prostaglandin infusion (0.025–0. 05 μg · kg−1
), 10 had received dopamine (3–5 μg · kg−1
), 13 had received digoxin and lasix, and 4 had inspired a hypoxic gas mixture (17–19% Fio2
) by spontaneous ventilation in a hood. There were 12 full-term birth infants and 3 prematurely (< 37 weeks) born infants. None of the infants had neurologic abnormalities by history or physical examination.
During the study, 8 of 15 subjects received hypoxic mixture first followed by 3% Fico2
. Because neither the order of treatments (crossover effect, P
= 0.16) or time (period effect, P
= 0.45) was statistically significant, data are presented by condition (i.e.
, baseline) rather than by treatment order (baseline, 3% Fico2
, baseline, 17% Fio2
, baseline; or baseline, 17% Fio2
, baseline, 3% Fico2
, baseline). Mean data from the 15 subjects are shown in table 2
, and the change from baseline (δ) in the MAP and Sco2
for each subject is shown in table 3
Heart rate, systolic arterial pressure, and Sao2
did not change significantly with either Fico2
). With 3% Fico2
, diastolic arterial pressure and MAP increased significantly by 12 and 10%, respectively. During 17% Fio2
, diastolic arterial pressure and MAP did not change significantly (P
= 0.02 and 0.11, respectively). With 3% Fico2
H decreased and arterial carbon dioxide tension increased as intended, and arterial oxygen tension increased (P
< 0.01); although the base excess increased, it was not significant (P
= 0.09). With 17% Fio2
H increased and arterial oxygen and carbon dioxide tensions decreased (although no alterations were made to the minute ventilation, adding nitrogen increased the minute ventilation;P
< 0.01); the decrease in base excess was not significant (P
= 0.3). Nasopharyngeal temperature remained unchanged during the study (36 ± 0.4 vs.
35.98 ± 0.4°C, start vs.
end), as did hematocrit (42 ± 6 vs.
42.6 ± 6%, start vs.
Cerebral Oxygen Saturation
shows a typical tracing of Sco2
during the study in one subject, and table 4
shows the results of the 15 subjects. Sco2
increased significantly with 3% Fico2
< 0.01), whereas it did not change with 17% Fio2
= 0.85). In 8 of 15 subjects, 17% Fio2
, the largest decrease being 6.5%. By comparison ,
in all subjects, the largest increase being 26%. At baseline, in two subjects Sco2
was less than 40% (37 and 38.5%, respectively). In one of these subjects, Sco2
decreased to 32% with 17% Fio2
, whereas Sco2
increased to 48% with 3% Fico2
. In the other subject, Sco2
did not change with 17% Fio2
, but increased 10% during 3% Fico2
Increase in Sco2 began 2 ± 0.8 min after administration of 3% Fico2, and the increase was linear at a rate of 0.075 ± 0.05% · mmHg CO2−1 · min−1 (r2 = 0.68). With the discontinuation of Fico2, Sco2 returned to baseline by 8 ± 1.5 min. The relation between change in Sco2 and MAP during Fico2 was not significant (r2 = 0.27, P = 0.048). The Sco2 response to 3% Fico2 in the premature (10 ± 3%) and full-term birth (13 ± 6) infants was similar.
There were no complications from the study.
In this group of neonates with SV heart defects, we found that Sco2 and arterial pressure increased with 3% Fico2, whereas these parameters did not change significantly with 17% Fio2. These observations suggest that 3% Fico2 provides better preoperative hemodynamics and cerebral oxygenation than 17% Fio2 in this patient population.
Previous studies conducted in immature animal models of SV heart defects reported increases in pulmonary vascular resistance and a decrease in pulmonary to systemic blood flow ratios (Q̇p:Q̇s) with 10% Fio2
and 5% Fico2
However, no cerebral oxygenation or vital organ blood flow data exist in either animal model or human neonates. In anesthetized, mechanically ventilated human neonates with SV heart defects, Tabbutt et al.13
compared the impact of 17% Fio2
and 3% Fico2
on systemic oxygen delivery after the same protocol as our study. 13
They found that both treatments decreased Sao2
and Q̇p:Q̇s similarly, although 3% Fico2
increased systemic oxygen delivery, whereas 17% Fio2
had no significant impact. These data suggest that 3% Fico2
provides better systemic hemodynamics and oxygenation than 17% Fio2
. Our observations support these conclusions. However, lower inspired oxygen concentrations, as in the animal models, might provide a similar hemodynamic result as 3% Fico2
, with or without changes in cerebral oximetry.
Cerebral oximetry is an emerging technology to noninvasively monitor brain tissue oxygenation at the bedside. It is particularly applicable to the critically ill neonate and infant population, where the thin extra-cranial tissues do not interfere with brain monitoring, and in whom diagnosis of cerebral hypoxia–ischemia is otherwise problematic. At present, the instrumentation is based on continuous-wave or frequency-domain technologies. Continuous-wave devices have been commercially available for several years. They can monitor changes in Sco2 over time but cannot determine baseline levels accurately. Frequency-domain devices (used in this study), a new technology using cellular phone technology, can accurately determine baseline Sco2 as well as changes over time. It should be commercially available in the near future. However, the clinical utility of cerebral oximetry remains to be determined. Our study serves as an example of how the technology might be used clinically.
Cerebral oximetry and pulse oximetry differ in several respects. Although both use near-infrared light intensity signals, pulse oximetry monitors the pulsatile signal component reflecting the arterial circulation. Cerebral oximetry monitors the nonpulsatile signal component reflecting the gas-exchanging tissue circulation (capillaries, venules, arterioles), of which approximately 85% of the signal appears to originate from small venules. 11
Pulse oximetry often fails with poor perfusion as the pulsatile signal diminishes. Cerebral oximetry is not susceptible to this failure, although it is subject to motion artifact like pulse oximetry. The critical cerebral oxygen saturation that results in brain damage remains uncertain. Studies in animal models suggest that the risk of brain damage increases as Sco2
decreases to less than 40%, because electroencephalogram activity begins to slow, adenosine triphosphate decreases, and cytochrome aa3
becomes reduced; these physiologic changes inevitably lead to neuronal necrosis. 14
In our study, Sco2
was less than this 40% threshold in two subjects at baseline (incidence, 2 of 15 [13%]), which decreased further with 17% Fio2
in one subject, whereas Sco2
increased above the threshold in both subjects with 3% Fico2
. Based on this limited experience, 17% Fio2
might increase the risk of cerebral hypoxia–ischemia before surgery in this patient population.
Cerebral oxygen saturation reflects a balance between cerebral oxygen delivery and cerebral oxygen consumption. Cerebral oxygen delivery is a product of cerebral blood flow (CBF) and arterial oxygen content. The latter depends on Sao2
and hemoglobin. We did not measure hemoglobin, but during the study period there were no volume shifts; hence, use of hematocrit should be appropriate. During the study, Sao2
and hematocrit remained constant; thus, a change Sco2
resulted from changes in CBF or cerebral oxygen consumption. Hypercapnia and hypoxia in the magnitude used in our study do not alter cerebral oxygen consumption, 15
nor do they alter the proportion of arterial to venous blood in the brain. 11
Thus, changes in Sco2
most likely reflect changes in CBF.
Treatment with 3% Fico2 increased Sco2. The decrease in p H with hypercapnia would lead to a right shift in the oxygen dissociation curve (Bohr effect), which would lead to a decrease in Sco2 and not an increase. There was a small (3 mmHg) but significant increase in arterial oxygen tension with 3% Fico2 treatment; however, this cannot explain the 12% increase in Sco2 we observed. Hence, it is most likely that hypercapnic cerebral vasodilatation led to an increase in CBF with an increase in Sco2.
Healthy adult volunteers breathing hypoxic mixtures (7–11% Fio2
) during isocapnic conditions showed decreases in Sco2
We had therefore expected treatment with 17% Fio2
to lead to a decrease in Sco2
. However, the lack of change in Sco2
reflects the fact that cerebral oxygen delivery was unchanged. Hypoxia can lead to cerebral vasodilatation, but 17% Fio2
was an insufficient stimulus to evoke this. For example, in adult volunteers, CBF did not change with 18% Fio2
, and it increased only 5% in response to 16% Fio2
Cerebral blood flow may also increase if the MAP increases above the limits of autoregulation. The upper lower limit of autoregulation is uncertain in human neonates but is approximately 90 mmHg in neonatal animals. 18,19
In our study, mean arterial pressure increased 10% in response to 3% Fico2
but was still within the limits of autoregulation. Hence, an increase in CBF, and hence Sco2
, on this basis was unlikely.
There are several limitations in our study that might not allow generalization of our findings to care of neonates with SV in the intensive care unit. Our subjects were anesthetized and mechanically ventilated. Their baseline and posttreatment Sao2
were greater than that of nonanesthetized, spontaneously breathing subjects. It is possible that the response to hypoxic or hypercapnic gas mixtures differs in nonanesthetized, spontaneously breathing subjects with lower Sao2
. Despite treatment with 3% Fico2
and 17% Fio2
, the Sao2
remained greater than 90% in our subjects ,
indicating continued excessive pulmonary blood flow. Use of higher Fico2
or lower Fio2
might have reduced Sao2
further. Time constraints did not permit us to test this hypothesis. Time constraints also limited each baseline and treatment period to 10–20 min. Previous work has shown the CBF response to hypercapnia and hypoxia to be completed by 5 and 6 min, respectively, with return to baseline by 1–2 min. 17,20
Hence, treatment duration in our study should have been adequate to observe a response. However, chronic exposure (hours) might desensitize the cerebral response to hypoxia and hypercapnia.
In conclusion, we demonstrated that controlled ventilation with 3% Fico2 increased the cerebral oxygen saturation as well as arterial pressure, whereas controlled ventilation with 17% Fio2 maintained arterial pressure but did not change Sco2 in most subjects, suggesting these treatments provide hemodynamic stability but affect cerebral oxygenation differently. The impact of 17% Fio2 on cerebral oxygen saturation during spontaneous ventilation, prolonged administration of 17% Fio2 and 3% Fico2, as well as higher Fico2 remain to be studied.
1. Mora GA, Pizarro C, Jacobs ML, Norwood WI: Experimental model of single ventricle: Influence of carbon dioxide on pulmonary vascular dynamics. Circulation 1994; 90: 43–36
2. Jobes DR, Nicolson SC, Steven JM, Miller M, Jacobs ML, Norwood WI Jr: Carbon dioxide prevents pulmonary overcirculation in hypoplastic left heart syndrome. Ann Thorac Surg 1992; 54: 150–1
3. Rogers BT, Msall ME, Buck GM, Lyon NR, Norris MK, Roland JM, Gingell RL, Cleveland DC, Pieroni DR: Neurodevelopmental outcome of infants with hypoplastic left heart syndrome. J Pediatr 1995; 126: 496–8
4. Kern JH, Hinton VJ, Nereo NE, Hayes CJ, Gersony WM: Early developmental outcome after the Norwood procedure for hypoplastic left heart syndrome. Pediatrics 1998; 102: 1148–52
5. du Plessis AJ: Mechanisms of brain injury during infant cardiac surgery. Semin Pediatr Neurol 1999; 6: 32–47
6. Pua HL, Bissonnette B: Cerebral physiology in paediatric cardiopulmonary bypass. Can J Anaes 1998; 45: 960–78
7. Kurth CD, Steven JM, Benaron DA, Chance B: Near infrared monitoring of the cerebral circulation. J Clin Monit 1993; 9: 163–70
8. Kurth CD, Steven JM, Montenegro LM, Watzman HM, Gaynor JW, Spray TL, Nicolson SC: Cerebral oxygen saturation before congenital heart surgery. Ann Thorac Surgery 2001; 72: 187–92
9. Kurth CD, Steven JM, Nicolson SC, Jacobs ML: Cerebral oxygenation during cardiopulmonary bypass in children. J Thorac Cardiovasc Surg 1997; 113: 71–8
10. Kurth CD, Thayer WS: A multiwavelength frequency-domain near-infrared cerebral oximeter. Phys Med Biol 1999; 44: 727–40
11. Watzman HM, Kurth CD, Montenegro LM, Rome J, Steven JM, Nicolson SC: Arterial and venous contributions to near-infrared cerebral oximetry. A nesthesiology 2000; 93: 947–53
12. Reddy VM, Liddicoat JR, Fineman JR, McElhinney DB, Klein JR, Hanley FL: Fetal model of single ventricle physiology: Hemodynamic effects of oxygen, nitric oxide, carbon dioxide, and hypoxia in the early postnatal period. J Thorac Cardiovasc Surg 1996; 112: 437–49
13. Tabbutt S, Ramamoorthy C, Montenegro LM, Durning SM, Godinez RI, Kurth CD, Steven JM, Spray TL, Wernovsky G, Nicolson S: Impact of inspired gas mixtures on pre-operative infants with hypoplastic left heart syndrome (HLHS) during controlled ventilation (abstract). Circulation 2000; 102 (suppl II): II-469
14. Nioka S, Chance B, Smith DS, Mayevsky A, Reilly MP, Alter C, Asakura T: Cerebral energy metabolism and oxygen state during hypoxia in neonate and adult dogs. Pediatr Res 1990; 28: 54–62
15. Siesjo BK: Brain Energy Metabolism, 1st Edition. New York, Wiley, 1978, pp 288–304
16. Henson LC, Calalang C, Temp JA, Ward DS: Accuracy of a cerebral oximeter in healthy volunteers under conditions of isocapnic hypoxia. A nesthesiology 1998; 88: 58–65
17. Shapiro W, Wasserman AJ, Baker JP, Patterson JL Jr: Cerebrovascular response to acute hypocapnic and eucapnic hypoxia in normal man. J Clin Invest 1970; 49: 2362–8
18. Chemtob S, Barna T, Beharry K, Aranda JV, Varma DR: Enhanced cerebral blood flow autoregulation in the newborn piglet by d-tubocurarine and pancuronium but not by vecuronium. A nesthesiology 1992; 76: 236–44
19. Purves MJ, James IM: Observations on the control of cerebral blood flow in the sheep fetus and newborn lamb. Circ Res 1959; 25: 651–67
20. Ellingsen I, Hauge A, Nicolaysen G, Thoresen M, Walloe L: Changes in human cerebral blood flow due to step changes in PaO2 and PaCO2. Acta Physiol Scand 1987; 129: 157–63
© 2002 American Society of Anesthesiologists, Inc.